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LEVOCaBASTINE and azelastine are currently the
only antihistamines available as nasal sprays for
the topical therapy of seasonal allergic rhinitis.
The present study was undertaken to compare
the onset of action, efficacy and tolerability of
these two agents in a total of 242 patients with
th/s condition. This was an international, multi-
centre, open-label, randomized, parallel-group
trial with 123 patients treated with levocabastine
(0.5 mg/ml, two puffs per nostril twice daily) and
119 with azelastine (1 mg/ml, one puff per nostril
twice daily). Onset of action was comparable for
the two drugs with over 50% of patients in each
group reporting significant symptomatic relief
within 30 min of administration of the first dose
of study medication. Therapeutic efficacy was
also found to be comparable in the two groups
with no statistically significant intergroup differ-
ences reported for any of the parameters eval-
uated, although assessments of global therapeutic
efficacy revealed a trend favouring levocabastine.
Levocabastine appeared to be better tolerated
than azelastine (p 0.06), with the incidence of
the most common adverse experiences, applica-
tion site reactions and taste disturbances, sig-
nificantly higher on azelastine than with
levocabastine (5% versus 1%; p 0.05 and 5%
versus 0%; p 0.01, respectively). In conclusion,
levocabastine nasal spray appears to be at least as
effective as, but better tolerated than, azelastine
nasal spray for the treatment of seasonal allergic
rhinitis.
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Introduction
In recent years there has been renewed inter-
est in the topical treatment of allergic rhino-
conjunctivitis. A topical agent may be expected
to have a number of advantages over an orally
administered drug including a more rapid onset
of action, since the active agent is administered
directly to the affected site, and a reduced poten-
tial for unwanted systemic reactions. To date,
only two antihistamines are available for the
topical treatment of seasonal allergic rhinitis,
levocabastine and azelastine.
Levocabastine has been specifically developed
for topical use, and is available as both eye
drops and nasal spray. In vitro studies have
demonstrated that it is the most potent anti-
histamine available to date,
2 being 1000 times
more potent than azelastine in the compound
48/80 lethality test in rats. Comparative clinical
trials have shown topically applied levocabastine
to be well tolerated and at least as effective as
the oral antihistamines terfenadine and loratadine
forthe treatmentofseasonal allergic rhinoconjuncti-
vitis,4-7 with statistically significant differences in
favour of the topical drug observed in some
studies.4’5 In contrast, azelastine has p_rimarily
been developed as an anti-asthma agent,
8 and is
only available as a nasal spray. In addition to its
antihistaminic activity, this agent appears to have
other anti-allergic properties which may be of
clinical benefit to patients with allergic rhinitis. In
clinical trials, intranasal azelastine has been
shown to be as effective as oral terfenadine, aste-
mizole and loratadine for the treatment of
patients with this allergic disorder.9’
As no direct comparison of these two topical
antihistamines has been undertaken to date, the
present study was initiated to compare the effi-
cacy, onset of action and tolerability of levoca-
bastine and azelastine nasal sprays in patients
with seasonal allergic rhinitis. The study was
open-label, rather than blinded, as with a nasal
spray the design of the delivery device may influ-
ence therapeutic efficacy. Furthermore, the
levocabastine and azelastine nasal sprays
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commercially available deliver different volumes patients under 18 years of age recruited for the
necessitating different dosage regimens. Conse- Belgian part of the study
quently, topical placebos would be required to
fully blind treatment. Response rates as high as Assessments and evaluations.. The severity of
35% have been reported with placebo nasal sneezing, rhinorrhoea, nasal itching, nasal con-
sprays which may distort any true differences in gestion and concurrent ocular symptoms was
therapeutic efficacy between the two treatment assessed by the patients on a daily basis and by
groups.
1 the investigator at the start of the trial, after 1
week of treatment and at the study end-point,
Materials and Methods using a 4-point scale (0 absent, 1 mild
[noticeable on occasion but not bothersome], 2
Patients: Patients aged between 12 and 70 years moderate [noticeable from time to time and
with at least a 1-year history of seasonal allergic tended to be bothersome], 3 severe [frequent
rhinitis severe enough to require anti-allergic and bothersome]). Patients also assessed the
therapy, together with a positive skin prick and/ overall severity of their rhinitis on a daily basis
or (radioallergosorbent) RAST test for grass using a 100 mm visual analogue scale (VAS;
pollen were eligible for entry into this trial. In extremes; 0 absent, 100 very severe). In
addition, patients were required to exhibit at addition, both the patients and investigator per-
least two typical nasal symptoms of moderate formed global evaluations of treatment efficacy at
severity at the time of entry into the trial. The the end of the trial rating the effect of therapy as
trial was performed between 1 May 1993 and 15 excellent, good, moderate or poor.
August 1993 at the height of the grass pollen To permit evaluation of onset of action,
season, patients were asked to record the overall severity
Exclusion criteria included: concurrent dis- of rhinitis symptoms on a diary card using a 100
eases which could interfere with assessment of mm visual analogue scale (VAS; extremes: 0
the study drugs such as vasomotor rhinitis, rhini- absent, 100 very severe) immediately before
tis medicamentosa, active infective sinusitis, taking the first dose of study medication and
upper respiratory tract infections and large then at 5, 10, 20, 30 and 40 min, and 1, 2, 3, 4, 6
obstructive nasal polyps; concomitant therapy and 8 h after administration. In addition, patients
with any medication that might interfere with the were requested to indicate how soon they felt
assessment of the study drugs with a washout significant improvement in rhinitis symptom
period of 1 month for systemic corticosteroids, 2 severity following administration of the first dose
weeks for topical corticosteroids and sodium of study medication.
cromoglycate, 1 week for all antihistamines with Any adverse events experienced during the
the exception of astemizole for which a washout trial were recorded by the patients in their
period of 6 weeks was required, and 3 days for diaries. Pollen counts were performed daily at
decongestants and all other ocular and nasal each centre. Pollen counts greater than 50 pollen
medication; concurrent hyposensitization therapy; grains/mm were classed as high.
and use of an investigational drug within 30 days
prior to entry into the trial. Patients with evi- Statistical analysis.. An intention-to-treat analysis
dence of major organ disease, and pregnant or was performed. Onset of action was derived
nursing women were also excluded from partici- from the patients’ diary data generated following
pation in the study, administration of the first dose of study medica-
tion. In addition to the individual symptoms
Study design: This was an international (Belgium, listed above, the sum of all nasal symptoms and
Germany), multicentre, open-label, parallel-group the sum of all symptoms were calculated and
trial. Although the study was open, treatment was analysed at the start of the trial and at the end of
randomized and the two antihistamine sprays the 1-week treatment period. Daily VAS ratings of
were supplied in identical packaging. Patients symptom severity, the area under the curve
received either levocabastine nasal spray (0.5 mg/ (AUC) for the different VAS scores (expressed as
ml) two puffs per nostril twice daily or azelastine a percentage of the maximal AUC and calculated
nasal spray (1 mg/ml) one puff per nostril twice using the trapezoidal rule), the percentage of
daily. Treatment duration was 1 week. The study days with severe symptoms (VAS > 50%) and
was conducted in accordance with the Declara- the percentage of symptom-free days (VAS <
tion of Helsinki and subsequent revisions. The 10%) were also determined for all parameters
study protocol was approved by the local ethics recorded in the patients’ diaries. The influence of
committee and all patients gave informed the pollen count on the daily symptom scores
consent, with informed parental consent for was also evaluated. All intergroup differences
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Table 1. Patient demographics
Levocabastine Azelastine
Number of patients 123 19
(male/female) (55/68 66/53
Median age in years 30.0 30.0
(range) (12-65) (12-69)
Median weight in kg 67.0 68.0
(range) (33-105) (36-133)
were subjected to
(ANOVA).
analysis of variance testing
Results
A total of 242 patients were entered into this
trial, 123 of whom received levocabastine and
119 azelastine. Patient demographics are shown
in Table 1. In all, 17 patients withdrew from the
trial (six levocabastine-treated patients and eleven
of those on azelastine). Reasons for withdrawal
are summarized in Table 2. Adverse experiences
resulting in withdrawal included dry throat
(levocabastine), cough (azelastine) and dyspnoea
with wheezing (azelastine). As shown in Table 3,
baseline symptom severity was generally compar-
able in the two treatment groups, although total
symptom severity was found to be 7% higher in
the azelastine treatment group than in the group
Table 2. Reasons for withdrawal in the two treatment groups
Levocabastine Azelastine
(n= 123) (n= 119)
Number of patients 6
Reason*
Adverse experience 3
Insufficient response 2 4
Lost to follow-up 3
Lack of symptoms
Uncooperative 2
Other 2
*Some patients gave more than one reason for withdrawal.
Table 3. Investigator assessments of symptom severity in the
two treatment groups at baseline and at the end of the trial
Levocabastine Azelastine
Baseline Endpoint Baseline Endpoint
Sneezing 2.2 0.7 2.3 0.7
Rhinorrhoea 2.2 0.8 2.4 0.8
Nasal itching 1.8 0.6 1.8 0.6
Nasal congestion 1.9 1.0 2.1 1.1
Ocular symptoms 1.7 0.6 1.8 0.6
Total nasal symptoms 8.1 3.1 8.6 3.2
Total all symptoms 9.8 3.6 10.5" 3.8
REach symptom was assessed using a 4-point scale (0 absent, mild,
2 moderate, 3 severe).
*0.05 < p < 0.1.
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FIG. 1. Investigator evaluation of global therapeutic efficacy at
the end of the 1-week treatment period. L levocabastine, A
azelastine.
which received levocabastine at the start of the
trial (0.05 < p < 0.1).
Pollen concentrations were considered suffi-
cient to elicit symptoms of seasonal allergic rhini-
tis in both countries throughout the trial period
with high counts recorded on 79% of study days.
Assessments of global therapeutic efficacy
were found to favour levocabastine, however
intergroup differences did not attain statistical
significance. At the end of the trial, the investi-
gator rated therapeutic efficacy as excellent or
good in 70% of levocabastine-treated patients
compared with 63% of those who received aze-
lastine (Fig. 1). The corresponding values for the
patients’ assessments were 68% and 61% in the
two groups, respectively.
Both the investigators’ and patients’ assess-
ments revealed that levocabastine and azelastine
provided comparable reduction of symptom
scores for sneezing, rhinorrhoea, nasal itching,
nasal congestion and concurrent ocular symp-
toms, as well as total symptom severity (Table 3,
Figs 2 and 3), with a similar percentage of
Sneezing L
A
Rhinorrhoea L
A
Nasal itching L
A
Nasal congestion L
A
Ocular symptoms L
A
Total nasal L
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Total all L
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FIG. 2. Patient evaluations of symptom severity during the 1-
week trial expressed as a percentage of the maximum AUC for
each variable (___ SEM).
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FIG. 3. Patient evaluations of symptom severity during the 1-
week trial. Day-by-day score for all symptoms combined (mean
4- SEM).
Table 4. Adverse experiences occurring in at least two patients
per treatment group
Levocabastine Azelastine
(n= 120) (n= 118)
n % n %
Number of patients reporting 13 10.8 23 19.5
an adverse experience
Adverse experience
Application site reaction 0.8 6 5.1
Taste disturbance 6 5.1
Rhinitis 2 1.7 3 2.5
Headache 3 2.5 0.8
Fatigue 2 1.7 2 1.7
Injury 3 2.5
Pharyngitis 2 1.7 0.8
Bronchospasm 2 1.7
Abdominal pain 2 1.7
symptom-free days in the two treatment groups
(7% on levocabastine compared with 9% on aze-
lastine). Analysis as a function of pollen count
also failed to reveal any significant intergroup dif-
ferences in therapeutic efficacy on days with high
pollen counts.
Onset of action was found to be comparable
for the two drugs as assessed by patients’ VAS
ratings following administration of the first dose
of study medication. More than half the patients
in each treatment group reported relief of symp-
toms within 30 min of drug application (53% on
levocabastine and 54% on azelastine). Relief from
symptoms was found to be maintained at 8 h
after administration of the first dose of study
medication in both treatment groups.
(p 0.06) (Fig. 4). As shown in Table 4, the
most commonly reported adverse events were
application site reactions and taste disturbances.
These were significantly more frequent in the
azelastine group than in the group treated with
levocabastine, with application site reactions
reported by 5% of patients on azelastine com-
pared with 1% of those who received levocabas-
tine (p 0.05) and taste disturbances by 5%
and 0% of patients in the two groups, respec-
tively (p 0.01). No significant intergroup dif-
ferences in frequency were apparent for any of
the other common adverse reactions reported.
The incidence of adverse experiences was Discussion
found to be higher on azelastine than levocabas-
tine, with adverse reactions reported by 19% and
11% of patients in the two groups respectively
p 0.06
19%
11%
L A
FIG. 4. Percentage of patients reporting adverse experiences in
the two treatment groups.
The results of this study suggest that levoca-
bastine and azelastine nasal sprays have compar-
able efficacy in patients with seasonal allergic
rhinitis with both agents providing rapid, effec-
tive and sustained symptomatic relief. Although
both the investigators’ and the patients’ assess-
ments of global therapeutic efficacy revealed a
trend in favour of levocabastine, no statistically
significant intergroup differences were seen for
any of the efficacy parameters evaluated. This is
in keeping with the results of previous studies
which have shown that these two topical anti-
histamines are at least as effective as oral H-
receptor antagonists for the treatment of this
common condition.4-r’9
The effects of levocabastine and azelastine
were comparable on all symptoms of allergic rhi-
nitis, including nasal congestion. Nasal conges-
tion is generally less responsive to treatment with
antihistamines, although it has been claimed that
azelastine is particularly effective for the treat-
ment of this symptom due to its anti-inflamma-
12 tory properties. However, the results of the
present study suggest the effect of levocabastine
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on nasal congestion is at least as good as that
seen with azelastine.
In this trial, levocabastine nasal spray was
clearly better tolerated with the overall incidence
of adverse experiences markedly higher in aze-
lastine-treated patients than in those who
received levocabastine (19% versus 11%; p
0.06). As might be expected from the route of
drug administration, application site reactions
and taste disturbances were the most frequent
adverse events occurring during the course of
the trial. However, the incidence of these reac-
tions was found to be significantly greater in
patients on azelastine than with levocabastine
(5% versus 1% for application site reactions; p
0.05 and 5% versus 0% for taste disturbances;
p 0.01, respectively).
Topical antihistamines such as levocabastine
and azelastine represent a significant advance in
antihistamine research and provide a useful alter-
native to oral antihistamines as a therapeutic
option for the treatment of patients with allergic
rhinitis. Results of this initial comparative study
suggest that the two agents have similar ther-
apeutic efficacy, but that levocabastine nasal
spray is better tolerated. Coupled with the fact
that this agent is also available as eye drops for
the relief of concurrent ocular symptoms, these
findings suggest that levocabastine may be the
preferred topical antihistamine for the treatment
of allergic rhinoconjunctivitis.
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